Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by Speyeder999on Apr 09, 2022 12:18pm
204 Views
Post# 34590705

Annual General Meeting

Annual General Meeting
Looking forward to the general annual meeting. Questions can be submitted before and during meeting, hopefully they can shed a little more light on the timeline/progress.

Panning through the management circularr for the meeting and find it somewhat odd
that 4 directors own ZERO shares of the company
(ie: Mandel Brehm, Grgory, Shafmaster, Warma)
but some do have options. Wow, that's quite an endorsement for the company they work for, heh?

5) Each of the following director nominees holds options to purchase Common Shares: Dr. Gregory (1,000,000), Ms. Shafmaster (500,000), Mr. Warma (500,000); Mr. Williams (10,948,583) and Mr. Wyman (1,200,000).

<< Previous
Bullboard Posts
Next >>